Try our new research platform with insights from 80,000+ expert users

Contrast Security Assess vs IMMUNIO [EOL] comparison

 

Comparison Buyer's Guide

Executive Summary

Review summaries and opinions

We asked business professionals to review the solutions they use. Here are some excerpts of what they said:
 

Categories and Ranking

Contrast Security Assess
Average Rating
8.8
Reviews Sentiment
7.2
Number of Reviews
11
Ranking in other categories
Application Security Tools (29th), Static Application Security Testing (SAST) (27th)
IMMUNIO [EOL]
Average Rating
0.0
Number of Reviews
0
Ranking in other categories
No ranking in other categories
 

Featured Reviews

ToddMcAlister - PeerSpot reviewer
Lead Application and Data Security Engineer at a insurance company with 5,001-10,000 employees
It has an excellent API interface to pull APIs.
Assess has brought our development time down because it helps create code the first time. Instead of going through the Jenkins process to build an application, they can see right off the bat that if there are errors in the code and fix them before it even goes to build.
Use IMMUNIO [EOL]?
Leave a review
report
Use our free recommendation engine to learn which Application Security Tools solutions are best for your needs.
885,286 professionals have used our research since 2012.
 

Top Industries

By visitors reading reviews
Financial Services Firm
19%
Manufacturing Company
11%
Computer Software Company
7%
Comms Service Provider
7%
No data available
 

Company Size

By reviewers
Large Enterprise
Midsize Enterprise
Small Business
By reviewers
Company SizeCount
Small Business2
Midsize Enterprise3
Large Enterprise6
No data available
 

Also Known As

Contrast Assess
No data available
 

Overview

 

Sample Customers

Williams-Sonoma, Autodesk, HUAWEI, Chromeriver, RingCentral, Demandware.
SurveyMonkey, Nuna, Involvio, Toptal
Find out what your peers are saying about SonarSource Sàrl, Checkmarx, Veracode and others in Application Security Tools. Updated: February 2026.
885,286 professionals have used our research since 2012.